沙美特罗替卡松粉吸入剂联合噻托溴胺对慢性阻塞性肺疾病急性加重期患者肺功能及生命质量的影响  

Effects of salmeteroticasone powder inhalation combined with tiotrobromide on pulmonary function and quality of life in patients with acute exacerbation of chronic obstructive pulmonary disease

作　　者：占超群 张卓然[1] 李特 ZHAN Chaoqun;ZHANG Zhuoran;LI Te(Department of Respiratory Medicine,the Second Hospital of Huangshi,Huangshi,Hubei,435000,China)

机构地区：[1]黄石市第二医院呼吸科,湖北黄石435000

出　　处：《当代医学》2023年第16期48-51,共4页Contemporary Medicine

摘　　要：目的分析沙美特罗替卡松粉吸入剂联合噻托溴胺对慢性阻塞性肺疾病急性加重期(AECOPD)患者肺功能及生命质量的影响。方法选取2019年4月至2021年4月本院收治的92例AECOPD患者作为研究对象,按照随机数字表法分为参照组与病例组,每组46例。参照组采用沙美特罗替卡松粉吸入剂治疗,病例组采用沙美特罗替卡松粉吸入剂联合噻托溴胺治疗,比较两组临床疗效、血清炎症指标、肺功能、生命质量、不良反应发生率。结果病例组治疗总有效率为95.65%,高于参照组的69.57%,差异有统计学意义(P<0.05)。治疗前,两组肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、白细胞介素-6(IL-6)水平比较差异无统计学意义;治疗后,两组TNF-α、IL-8、IL-6水平均低于治疗前,且病例组低于参照组,差异有统计学意义(P<0.05)。治疗前,两组第1秒用力呼气容积(FEV_(1))、FEV_(1)占用力肺活量(FVC)比值(FEV_(1)/FVC)比较差异无统计学意义;治疗后,两组FEV_(1)、FEV_(1)/FVC均高于治疗前,且病例组高于参照组,差异有统计学意义(P<0.05)。治疗前,两组疾病对日常生活影响、活动能力、呼吸症状评分比较差异无统计学意义;治疗后,两组疾病对日常生活影响、活动能力、呼吸症状评分均低于治疗前,且病例组低于参照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义。结论沙美特罗替卡松粉吸入剂联合噻托溴胺可有效改善AECOPD患者肺功能和临床症状,减轻炎症反应,提升生命质量,且未增加不良反应,值得临床推广应用。Objective To investigate the effects of salmeteroticasone powder inhalation combined with tiotrobromide on pulmonary function and quality of life in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods A total of 92 AECOPD patients admitted to our hospital from April 2019 to April 2021 were selected as the research subjects,and they were divided into reference group and case group according to random number table method,with 46 cases in each group.The reference group was treated with salmeteroticasone powder inhalation,and the case group was treated with salmeteroticasone powder inhalation combined with tiotromomide,the clinical efficacy,serum inflammatory indexes,pulmonary function,quality of life and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the case group was 95.65%,which was higher than 69.57%in the reference group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the levels of tumor necrosis factor-α(TNF-α),interleukin-8(IL-8)and interleukin-6(IL-6)between the two groups;after treatment,the levels of TNF-α,IL-8 and IL-6 of the two groups were lower than before treatment,and the case group was lower than the reference group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in forced expiratory volume in one second(FEV_(1))and FEV_(1)/forced vital capacity(FVC)ratio(FEV_(1)/FVC)between the two groups;after treatment,the FEV_(1)and FEV_(1)/FVC of the two groups were higher than those before treatment,and the case group was higher than the reference group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in the scores of impact of disease on daily life,activity ability and respiratory symptoms between the two groups;after treatment,the scores of impact of disease on daily life,activity ability and respiratory symptoms of the two g

关 键 词：沙美特罗替卡松粉吸入剂 噻托溴胺 慢性阻塞性肺疾病急性加重期 肺功能 生命质量 

分 类 号：R563.9[医药卫生—呼吸系统]